Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astria Therapeutics ( (ATXS) ) has provided an update.
At a special meeting held on January 21, 2026, Astria Therapeutics stockholders approved the company’s acquisition by BioCryst Pharmaceuticals, with approximately 62.6% of outstanding shares represented and a strong majority voting in favor of the merger. Shareholders also backed, on a non-binding advisory basis, the merger-related compensation for named executive officers, and the parties indicated they expected the deal to close on or about January 23, 2026, signaling a major strategic shift for Astria as its pipeline of allergy and immunology therapies transitions under BioCryst’s ownership.
The most recent analyst rating on (ATXS) stock is a Sell with a $12.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.
Spark’s Take on ATXS Stock
According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.
The score is primarily held back by weak financial performance (pre-revenue profile, large losses, and rising cash burn), partially offset by a low-leverage balance sheet. Technicals are supportive with the stock trading above key moving averages and positive momentum, but valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on ATXS stock, click here.
More about Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company focused on developing life‑changing therapies for patients and families affected by allergic and immunologic diseases. Its lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema, while its second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
Average Trading Volume: 1,085,442
Technical Sentiment Signal: Hold
Current Market Cap: $711.8M
For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.